Loading
A phase 2 trial of Bevacizumab, Cemiplimab, Fianlimab in ovarian cancer, run by Regeneron Pharmaceuticals, now recruiting.
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT06787612 by Regeneron Pharmaceuticals, with 297 participants planned, started 2025-05-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ubamatamab, Regeneron, Cemiplimab, Ovarian cancer.
Shares Ubamatamab, Regeneron, Cemiplimab, Ovarian cancer.
Shares Fianlimab, Regeneron, Cemiplimab.
Shares Fianlimab, Regeneron, Cemiplimab.
Shares Fianlimab, Regeneron, Cemiplimab.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Bevacizumab, Ovarian cancer.
Shares Fianlimab, Regeneron, Cemiplimab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/